News | May 30, 2022
Glenmark Pharma reports revenue growth of 5.6% YoY in Q4
Glenmark Pharmaceuticals announced its financial results for the fourth quarter ended March 31, 2022
Glenmark Pharmaceuticals announced its financial results for the fourth quarter ended March 31, 2022
The inspection was a Pre-Approval cum cGMP inspection and it covered 15 ANDAs
Bempedoic acid helps lower cardiovascular risk in high or very high-risk atherosclerotic cardiovascular disease (ASCVD) patients as an add-on therapy to maximally tolerated statin and/or ezetimibe
This new fund is amongst the largest for the sector in India
It is a new class of drug that treats uncontrolled LDLCholesterol, despite the use of a maximum tolerated dose of statins
The drug will be manufactured at the group's formulation facility at SEZ, Ahmedabad
Glenmark Pharmaceuticals won Innovation of the Year award
The two-dose regimen for ZyCoV-D was tested in 3100 healthy volunteers more than 12 years of age
Desidustat is currently approved only in India as OxemiaTM for patients with CKD induced anemia
This product is indicated for the short-term treatment of a breathing problem (apnea) in premature infants
Subscribe To Our Newsletter & Stay Updated
